MEDIROM Healthcare Technologies Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Kouji Eguchi
- Full Time Employees
- 334
- Sector
- Consumer Cyclical
- Industry
- Personal Products & Services
- Address
- Tradepia Odaiba Tokyo TY Japan 135-0091
- IPO Date
- Dec 29, 2020
- CIK
- 0001819704
- Website
- medirom.co.jp
- Similar Companies
- Business
- MEDIROM Healthcare Technologies Inc. provides holistic health services in Japan through three primary segments: Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty; the Relaxation Salon segment develops, owns, operates, franchises, and supports salons offering finger-pressure style bodywork therapy, stretch therapy, posture and joint alignment, physical therapy elements, anti-fatigue therapy, athletic support therapy, slim-down therapy, and reflexology under the Re.Ra.Ku and Ruam Ruam brands; the Digital Preventative Healthcare segment delivers government-sponsored Specific Health Guidance programs via the Lav on-demand health monitoring smartphone application, MOTHER Bracelet wearable fitness and health tracker, REMONY remote monitoring system, and preventative services utilizing nutritionists and health nurses; and the Luxury Beauty segment manages hair salons under the ZACC brand. The company, founded in 2000 and headquartered at 2-3-1 Daiba, Minato-ku, Tokyo, Japan, primarily serves individual consumers and corporate clients across industries such as nursing care, transportation, construction, manufacturing, and government entities including the Japan Ground Self-Defense Force, with operations concentrated in Japan and aspirations for global expansion as a healthcare general trading company. Recent developments include the acquisition of a rehabilitation business from Y's, Inc. in July 2024, a share transfer agreement in June 2024 to acquire 70% of Japan Gene Medicine Corporation with an option for the remaining 30%, a memorandum of understanding in March 2024 for further share acquisition of Japan Gene Medicine, collaboration with Hakuhodo Inc. in July 2025 to join the World Network proof-of-human protocol co-founded by Sam Altman, adoption of REMONY by the Japan Ground Self-Defense Force and certification by the Ministry of Land, Infrastructure, Transport and Tourism as a fatigue-driving prevention device, surpassing 100 contracted companies and 10,000 supported individuals for Lav Specific Health Guidance services, internal investment in subsidiary MEDIROM MOTHER Labs Inc. at a JPY9 billion Series A valuation, and regaining NASDAQ compliance.
MEDIROM MOTHER Labs Expands Deployment of "REMONY®" Remote Health Monitoring System in JGSDF 8th Division
Micromem Technologies Inc. Update on Wearable Sensing Platform for Defence and Security Application Evaluation
Micromem Closes Private Placement
MEDIROM Group Reports Q1 2026 Results
Medirom Healthcare Technologies (NASDAQ:MRM) Shares Down 2.4% – Here’s What Happened
MEDIROM Launches Partnership with Tools for Humanity in February; Projects Approximately $39 Million in Income Before Income Taxes Over Two Years Following Expansion to 3,000 Nationwide Locations
MEDIROM Forms New Special Mission Team to Drive World ID Adoption Across 3,000 Locations Through Partnership with Tools for Humanity
MEDIROM Healthcare Technologies (NYSE:MRM) Shares Down 2.7% – What’s Next?
Critical Comparison: Regis (NASDAQ:RGS) and Medirom Healthcare Technologies (NASDAQ:MRM)
Enthorin Therapeutics Announces Initiation of Phase II Clinical Trial of MRM-3379 (Formerly ENT-3379) for Fragile X Syndrome by Licensing Partner Mirum Pharmaceuticals
World, Co-founded by Sam Altman and Alex Blania, Accelerates Expansion in Japan via MEDIROM Collaboration Re.Ra.Ku's “Orb” Authentication Surpasses 20,000 Cumulative Verifications, Doubling in Approximately Two Months
Financial Contrast: Medirom Healthcare Technologies (NASDAQ:MRM) and Regis (NASDAQ:RGS)
Comparing Medirom Healthcare Technologies (NASDAQ:MRM) and Regis (NASDAQ:RGS)
Analyzing Medirom Healthcare Technologies (NASDAQ:MRM) and Regis (NASDAQ:RGS)
MEDIROM Partners with World on Technology Envisioned by Sam Altman and Alex Blania: Deploying “Proof of Human” Infrastructure throughout Japan
Critical Analysis: Medirom Healthcare Technologies (NASDAQ:MRM) vs. Regis (NASDAQ:RGS)
MEDIROM Partners with World
Medirom Healthcare Technologies (NASDAQ:MRM) vs. Regis (NASDAQ:RGS) Head-To-Head Analysis
Mirum Pharmaceuticals Announces First Patient Enrolled in the BLOOM Phase 2 Clinical Study Evaluating MRM-3379 in Fragile X Syndrome
MEDIROM MOTHER Labs Inc. Receives Capital Investment from Internal Investors